503A and 503B compounding pharmacies face the most complex peptide procurement reality. Direct API import. FDA Import Alert exposure. Per-batch COA verification. Multi-state licensure compliance. The publication that covers it like a procurement consultant who has been in the room.
If you are running a 503A patient-specific compounding operation or scaling a 503B outsourcing facility, the procurement diligence you do at supplier qualification stage determines whether your pharmacy ends up with a clean inspection record or a 483. Most published guidance is either generic GMP material or marketing copy from suppliers themselves. Our coverage is editorial, supplier-independent, and built on first-hand sourcing experience.
The four operational risks specific to peptide API procurement that have driven 503A and 503B inspection findings over the last 24 months. None are theoretical. All have appeared in publicly available FDA inspection records.
Suppliers move on and off Import Alert 66-80 and 66-41. A supplier in good standing at PO submission can be on the Red List by delivery. Your incoming inspection process needs to verify status at receipt, not just at qualification.
Suppliers who provide one good COA at qualification and degraded quality on subsequent batches. A real supplier qualification program runs spot retesting on incoming batches at independent labs.
The HHS February 2026 reclassification moved 14 peptides back to Category 1, but Federal Register publication is still pending as of April 2026. Pharmacies acting on the announcement before formal publication face their own exposure.
Compounding agreements that work in one state may not work in another. Your supplier compliance documentation needs to be defensible against the strictest state board you ship into.
Five coverage areas specific to compounding pharmacy procurement. Each pillar has dedicated guides, blog posts, and reference tools.
How to read a supplier audit, what NMPA registration actually proves, and the GMP certificates that mean nothing.
Per-batch testing protocols, independent lab comparison, identifying fabricated COAs, what to retest in-house.
FDA Import Alert tracking, Category 1/2 reclassification monitoring, EU Written Confirmation as third-party signal.
Pricing benchmarks across China, Korea, US. FOB vs DDP terms. Lead time realities by region.
Supplier qualification SOPs that survive a 483. Documentation patterns that pass inspection.
A 30-page procurement reference for the four segments. Regulatory landscape, supplier vetting frameworks, COA interpretation, pricing benchmarks, red flags. Free download.
Get the Buyer’s Guide →